Cold agglutinin disease
MONDO:0018922Cold agglutinin disease is a type of autoimmune hemolytic anemia defined by the presence of cold autoantibodies (autoantibodies which are active at temperatures below 30B0C).
Also known as: CAD, CAS, chronic cold agglutinin disease, cold agglutinin syndrome, anemia, hemolytic, cold antibody, cold antibody disease, cold antibody hemolytic anaemia, cold antibody hemolytic anemia
58 clinical trials for this condition and its sub-types, 14 tagged with Cold agglutinin disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Can a new drug calm the immune System's attack on blood cells?
Disease control CompletedThis study is testing an experimental drug called povetacicept in adults with autoimmune cytopenias — conditions where the immune system mistakenly destroys blood cells, leading to low platelet counts (immune thrombocytopenia) or anemia (autoimmune hemolytic anemia and cold agglu…
Phase 1/2 • Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug shows promise for rare blood disorder
Disease control CompletedThis study tested a drug called pegcetacoplan in 24 adults with cold agglutinin disease, a rare condition where the immune system destroys red blood cells. Participants received either the drug or a placebo twice a week for 24 weeks. The goal was to see if the drug could raise he…
Phase 3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug BIVV020 tested for rare blood disorder
Disease control CompletedThis early-stage trial tested a single dose of the drug BIVV020 in 12 adults with cold agglutinin disease, a rare condition where the immune system mistakenly attacks red blood cells. The main goal was to see if the drug is safe and tolerable. Researchers also looked at how it af…
Phase 1 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Japanese CAD patients get continued access to experimental drug sutimlimab
Disease control CompletedThis study gave sutimlimab to 7 adults in Japan with cold agglutinin disease (CAD) who had already completed earlier trials and still needed treatment. The goal was to monitor safety and side effects over time until the drug became commercially available. It is a small, open-labe…
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 17:23 UTC